My watch list  

16 Newest Publications about the topic gleevec


You can refine your search further. Select from the filter options on the left to narrow down your results.

QnAs with Tony Hunter and James Allison [QnAs]

27-Jun-2017 | Prashant Nair, Proceedings of the National Academy of Sciences current issue, 2017

In the mid-1990s, the miracle drug Gleevec revolutionized cancer treatment, offering terminally ill patients with chronic myeloid leukemia (CML) a new lease on life. Until then, the only weapons in the medical arsenal against cancer were the blunt and brutal triad of surgery, radiation, and ...


Gleevec shifts APP processing from a {beta}-cleavage to a nonamyloidogenic cleavage [Neuroscience]

07-Feb-2017 | William J. Netzer; Karima Bettayeb; Subhash C. Sinha; Marc Flajolet; Paul Greengard; Victor Bustos, Proceedings of the National Academy of Sciences current issue, 2017

Neurotoxic amyloid-β peptides (Aβ) are major drivers of Alzheimer’s disease (AD) and are formed by sequential cleavage of the amyloid precursor protein (APP) by β-secretase (BACE) and γ-secretase. Our previous study showed that the anticancer drug Gleevec lowers Aβ levels through indirect ...


Identifying therapeutic targets in gastric cancer: the current status and future direction

01-Jan-2016 | Beiqin Yu; Jingwu Xie, Acta Biochimica et Biophysica Sinica, 2016

Gastric cancer is the third leading cause of cancer-related death worldwide. Our basic understanding of gastric cancer biology falls behind that of many other cancer types. Current standard treatment options for gastric cancer have not changed for the last 20 years. Thus, there is an urgent need ...


Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial Immunity

30-Mar-2015 | Ruth J. Napier et al., PLoS Pathogens, 2015

by Ruth J. Napier, Brian A. Norris, Alyson Swimm, Cynthia R. Giver, Wayne A. C. Harris, Julie Laval, Brooke A. Napier, Gopi Patel, Ryan Crump, Zhenghong Peng, William Bornmann, Bali Pulendran, R. Mark Buller, David S. Weiss, Rabindra Tirouvanziam, Edmund K. Waller, Daniel Kalman Imatinib ...


[Report] Using ancient protein kinases to unravel a modern cancer drug’s mechanism

20-Feb-2015 | C. Wilson; R. V. Agafonov; M. Hoemberger; S. Kutter; A. Zorba; J. Halpin; V. Buosi; R. Otten; D. Waterman; D. L. The ..., Science , 2015

Macromolecular function is rooted in energy landscapes, where sequence determines not a single structure but an ensemble of conformations. Hence, evolution modifies a protein’s function by altering its energy landscape. Here, we recreate the evolutionary pathway between two modern human ...


Efficient NQO1 Substrates are Potent and Selective Anticancer Agents

22-Aug-2013 | Elizabeth I. Parkinson; Joseph S. Bair; Megan Cismesia; Paul J. Hergenrother, ACS Chemical Biology, 2013

A major goal of personalized medicine in oncology is the identification of drugs with predictable efficacy based on a specific trait of the cancer cell, as has been demonstrated with gleevec (presence of Bcr-Abl protein), herceptin (Her2 overexpression), and iressa (presence of a specific EGFR ...


The DREAM Complex Mediates GIST Cell Quiescence and Is a Novel Therapeutic Target to Enhance Imatinib-Induced Apoptosis

15-Aug-2013 | Sergei Boichuk; Joshua A. Parry; Kathleen R. Makielski; Larisa Litovchick; Julianne L. Baron; James P. Zewe; Agniesz ..., Cancer Research, 2013

Gastrointestinal stromal tumors (GIST) can be successfully treated with imatinib mesylate (Gleevec); however, complete remissions are rare and patients frequently achieve disease stabilization in the presence of residual tumor masses. The clinical observation that discontinuation of treatment can ...


Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design

05-Jun-2013 | Blanc, Javier; Geney, Raphael; Menet, Christel, Anti-Cancer Agents in Medicinal Chemistry , 2013

Abstract: With the advent of the Type II kinase inhibitor imatinib (Gleevec) for treatment against cancer, rational design of tailored molecules has brought a revolution in medicinal chemistry for treating tumours caused by kinase malfunctioning. Among different types of kinase ...


Explaining why Gleevec is a specific and potent inhibitor of Abl kinase [Chemistry]

29-Jan-2013 | Yen-Lin Lin; Yilin Meng; Wei Jiang; Benoît Roux, Proceedings of the National Academy of Sciences current issue, 2013

Tyrosine kinases present attractive drug targets for specific types of cancers. Gleevec, a well-known therapeutic agent against chronic myelogenous leukemia, is an effective inhibitor of Abl tyrosine kinase. However, Gleevec fails to inhibit closely homologous tyrosine kinases, such as c-Src. ...


Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS) [Cell Biology]

02-Oct-2012 | Susanne B. Breitkopf; Min Yuan; German A. Pihan; John M. Asara, Proceedings of the National Academy of Sciences current issue, 2012

Hypothesis directed proteomics offers higher throughput over global analyses. We show that immunoprecipitation (IP)–tandem mass spectrometry (LC-MS/MS) in H929 multiple myeloma (MM) cancer cells led to the discovery of a rare and unexpected BCR–ABL fusion, informing a therapeutic intervention ...


Page 1 From 2
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE